The US Food and Drug Administration (FDA) has granted approval for Medtronic‘s MiniMed Connect, which provides a mobile connection to critical information for diabetes management.
MiniMed Connect is claimed to be the first product to allow diabetic patients to conveniently view their insulin pump and continuous glucose monitor (CGM) data on a smartphone.
The device provides healthcare teams with convenient access to comprehensive patient data so they can adjust their patients’ care plans.
Medtronic Diabetes Services and Solutions vice-president Annette Brüls said: "With MiniMed Connect, the entire care team can have access to critical diabetes data to inform the decisions that help people have better outcomes.
"The Connect platform represents how we will use leadership technologies, data and informatics to enable better therapy decision making and care for people with diabetes."
Comprising a small device that fits on a keychain or in a pocket, a smartphone app for the patient and a web display on desktop or mobile devices for care partners, MiniMed Connect transfers pump and sensor glucose data from the patient’s insulin pump to the app and web display.
The web display shows real-time sensor glucose and insulin information on the phone or any internet-enabled device anytime and anywhere, and is said to be available with iOS, Android or any other internet-enabled devices.
The smartphone app will initially be available with iOS devices.
Medtronic is working with Samsung to also develop an app for Android and optimise experiences on Samsung mobile devices.
Image: MiniMed Connect is designed to provide a mobile connection to critical information for managing diabetes. Photo: courtesy of Ambro / 2015 FreeDigitalPhotos.net.